Comparison of repaglinide with glibenclamide in the reduction of HbA1C of type 2 diabetic patients

Pakistan Journal of Medical and Health Sciences

Volumn 5, Issue 1, 2011, Pages 23-26

  Saleem, Khurram ^a   Yasin, Mohammad Ali ^b   Asrar, Anser ^c   Qamar, Samina ^a  

^a KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^b Social Security Hospital   (Pakistan)

^c LAHORE MEDICAL AND DENTAL COLLEGE   (Pakistan)

Author keywords

Glibenclamide; HbA1c; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; REPAGLINIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WEIGHT CHANGE;

EID: 84866361825     PISSN: 19967195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fuhlendorff J, Rossman P, Koyod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct process. Diabetes 1998; 47: 345-51.
2. Wolffenbuttel BHR, Nijst L, Sels JPJE, et al. Effects of a new oral hypoglycemic agent, repaglinide on metabolic control in sulfonyluea- treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-6.
3. Owens, Clauson P, Marbury TC, Winfeild K. A double- blind randomized comparison of meal related glycemic control by repaglinide and glyburide in well- controlled type 2 diabetic patients. Diabetic Care 1999; 22: 789-94.
4. Goldberg RB, Einhorn D, Lucas CP, et al.A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabet Care 1998; 21: 1897-903.
5. Damsbo P. Improved glycemic control with repaglinide in NIDDM with three times daily meal related dosing. Presented at the 57th science session of the ADA, Boston, MA.1997: abstract 0132.
6. Waldhausal W. Role of sulfonylureas in NIDDM: part-I - the pros. Horm Metab Res 1996; 28: 517-21. 7. Wolffenbuttel-BH. Repaglinide, a new compound for the treatment of patients with type 2 diabetes. Neth J Med 1999; 55(5): 229-34.
7. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999; 7: 139.
8. Pfeifer MA, Holter JB, Beard JC, Porte DJ. Differential effects of glibenclamide on first and second phase insulin secretion in NIDDM. J Clin Endocrinol Metab 1981; 53: 1256-62....
9. Ferner RE. Oral hypoglycemic agents. Med Clin North. Am 1988; 72: 1323-35.
10. Gromado J, Dissing S, Kofod H, Frokjar-Jensen J. Effects of the hypoglycemic drugs repaglinide and glibenclamide on ATP-sensitive K-channels and cytosolic calcium levels in BTC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-32.
11. Malaisse WJ. Repaglinide, a new oral antidiabetic agent, a review of recent preclinical studies. Eur J Clin Inves 1999; 29 suppl. 2: 21-9.
12. Rorsman P, Rolin B, Mackey P, Shymko R, Carr R. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct process. Diabetes 1998; 47: 345-51.
13. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, et al. A randomized placebo Controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetic Care 2000; 21(11): 1897-903.
14. Jovanovich L, Dailey G, Huang WC. Repaglinide-in type2 diabetes: a 24 week, fixed dose efficacy and safety. J Clinpharmacol 2000; 40(1): 49-57.
15. Landgraf R, Bilo HJ, Muller PG. Safety & efficacy Repaglinide compared with Glibenclamide in the management of type 2 diabetic patients.Eur J Clin Pharmacol. 1999 May; 55(2): 165-71.
16. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Prac. 2002 Oct: 58 (1): 45-53.